Citations 3
P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
Kumar, Shaji , Facon, T., Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, F., Weisel, Katja C , Moreau, Philippe , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent , Usmani, Saad Z.
HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 14-15
P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
Facon, T., Kumar, Seema, Plesner, Torben , Goldschmidt, H., Perrot, A., Venner, Chris , Mace, Joseph R., Tiab, Mourad, Macro, M. , Frenzel, L., Leleu, Xavier , Pei, H., Borgsten, F., Usmani, S. Z., Moreau, Philippe , Bahlis, Nizar Jacques , O’Dwyer, Michael , Weisel, Katja C , Raje, Noopur
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 826-827
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Popat, Rakesh , Hulin, Cyrille , Richardson, PG, Facon, T., Larsen, Jeremy T. , Minnema, M., Abdallah, Al-Ola, Badros, Ashraf , Knop, Stefan , Stadtmauer, Edward A. , Chen, M, Nguyen, Tiffany, Amin, Alpesh, Peluso, Teresa, Donk, Niels W.C.J. van de , Popat, Rakesh , Jagannath, Sundar , Oriol, Albert , Weisel, Katja C , Abdallah, Al-Ola , Lonial, Sagar
HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 14-15